companiesCompany

GRAIL

GRAIL developed Galleri, the multi-cancer blood test awaiting an FDA decision after a September 2026 advisory committee.

Galleri (PMA submitted January 2026), NHS-Galleri trial, PATHFINDER 2; spun out of Illumina in 2024.

Headquarters

Menlo Park, CA, US

Type

diagnostics · GRAL

Website

Products

Phase 3Multi-cancer early detection blood test

A blood test screening for more than 50 cancers at once, before the FDA in September 2026.

Connected

fronts

1

Early Detection & Screening

technologies

1

Multi-cancer early detection (MCED)

drugs

1

Phase 3Multi-cancer early detection blood test

institutions

2

Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre Prince of Wales Hospital / Chinese University of Hong Kong

ideas

4

An annual blinded shoot-out for liquid biopsy tests Multi-cancer blood test as the first step for patients with non-specific symptoms Pre-agreed update rules so an MCED test is not obsolete when its trial reads out Track clones in blood with methylation patterns instead of mutations

bottlenecks

1

Most lethal cancers are found late